Reference health
Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset
41/41 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 41 checked references that resolve
resolves10.1016/j.jare.2020.03.005
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
resolves10.1016/j.rbmo.2020.06.001
Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays
resolves10.1056/NEJMp2015897
False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications
resolves10.1080/14737159.2020.1757437
Real-time RT-PCR in COVID-19 detection: issues affecting the results
resolves10.1101/2020.08.05.20168476
Specificity and Performance of Nucleocapsid and Spike-based SARS-CoV-2 Serologic Assays
resolves10.1126/science.abb2762
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
resolves10.1101/2020.03.24.006544
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray
resolves10.1038/s41423-020-0385-z
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
resolves10.1101/2020.05.12.091462
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
resolves10.1016/j.celrep.2020.107918
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection
resolves10.1126/science.abc5902
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
resolves10.1038/s41586-020-2456-9
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
resolves10.1038/s41591-020-0965-6
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
resolves10.1038/s41392-020-00301-9
Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
resolves10.1093/cid/ciaa1143
Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
resolves10.1038/s41564-020-00813-8
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
resolves10.1056/NEJMoa2029849
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
resolves10.1001/jamainternmed.2020.4616
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China
resolves10.1101/2020.06.08.138990
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2
<i>In Vitro</i>
Virus Neutralization in Convalescent Plasma
resolves10.3389/fimmu.2020.01049
Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art
resolves10.1016/S0140-6736(20)31483-5
Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
resolves10.1172/JCI142004
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
resolves10.1038/s41590-020-00826-9
Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum
resolves10.1038/s41586-020-2538-8
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
resolves10.1038/s41467-020-17317-y
An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
resolves10.1101/2020.07.14.20151126
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
resolves10.1172/JCI138759
Kinetics of viral load and antibody response in relation to COVID-19 severity
resolves10.1126/science.abd3871
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
resolves10.1016/j.cell.2020.05.015
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
resolves10.1002/cpmc.100
SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
resolves10.1016/S0022-1759(98)00170-7
A statistically defined endpoint titer determination method for immunoassays
The 7 references without a DOI — listed, not checked
no DOI — not checkedJ. D. Whitman . Test performance evaluation of SARS-CoV-2 serological assays. medRxiv:10.1101/2020.04.25.20074856 (17 May 2020).
no DOI — not checkedJ. Kreye . A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. bioRxiv:10.1101/2020.08.15.252320 (16 August 2020).
no DOI — not checkedM. Papadimitriou-Olivgeris, K. Jaton, A. T. Coste, G. Greub, A. Croxatto, Comparison of SARS-CoV-2 serological tests with different antigen targets. J. Clin. Virol. 134, 104690 (2020).
no DOI — not checkedA. S. Iyer . Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv:10.1101/2020.07.18.20155374 (20 July 2020).
no DOI — not checkedWorld Health Organization Clinical management of COVID-19. https://www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed 11 January 2021.
no DOI — not checkedS. Kutsuna, Y. Asai, A. Matsunaga, Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N. Engl. J. Med. 383, 1695–1696 (2020).
no DOI — not checkedE. Terpos, A. Mentis, M. A. Dimopoulos, Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N. Engl. J. Med. 383, 1695 (2020).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1073/pnas.2021615118"><img src="https://citestamp.com/citestamped/10.1073/pnas.2021615118/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1073/pnas.2021615118)